Influence of Vitamin D on Inflammatory Bowel Disease Remission
The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2010 by Hillel Yaffe Medical Center.
Recruitment status was Not yet recruiting
Recruitment status was Not yet recruiting
Sponsor:
Hillel Yaffe Medical Center
Collaborator:
Technion, Israel Institute of Technology
Information provided by:
Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier:
NCT01121796
First received: May 10, 2010
Last updated: NA
Last verified: May 2010
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Vitamin D has been shown to influence a multitude of systems. We intend to see whether different types of Vitamin D supplements have an effect on inflammatory bowel disease.
| Condition | Intervention |
|---|---|
|
Inflammatory Bowel Disease |
Dietary Supplement: Vitamin D Other: Water or milk Dietary Supplement: Vitamin D enriched milk |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver) Primary Purpose: Treatment |
Resource links provided by NLM:
Further study details as provided by Hillel Yaffe Medical Center:
Primary Outcome Measures:
- Inflammatory disease remission [ Time Frame: One year ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 90 |
| Study Start Date: | June 2010 |
| Estimated Primary Completion Date: | June 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: Vitamin D | Dietary Supplement: Vitamin D |
| Placebo Comparator: Placebo | Other: Water or milk |
| Active Comparator: Unique vehicle for Vitamin D supplementation | Dietary Supplement: Vitamin D enriched milk |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Mild to moderate inflammatory bowel disease
Exclusion Criteria:
- Hypersensitivity to milk products
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01121796
Contacts
| Contact: Zvi Fireman, MD | fireman@hy.health.gov.il | |
| Contact: Oren Atia, MD | orena@hy.health.gov.il |
Locations
| Israel | |
| Hillel Yaffe Medical Center | Not yet recruiting |
| Hadera, Israel, 38100 | |
Sponsors and Collaborators
Hillel Yaffe Medical Center
Technion, Israel Institute of Technology
More Information
No publications provided
| Responsible Party: | Dr. Zvi Fireman, Director Gastroenterology Institute, Hillel Yaffe Medical Center |
| ClinicalTrials.gov Identifier: | NCT01121796 History of Changes |
| Other Study ID Numbers: | HY100510 |
| Study First Received: | May 10, 2010 |
| Last Updated: | May 10, 2010 |
| Health Authority: | Israel: Ministry of Health |
Additional relevant MeSH terms:
|
Inflammatory Bowel Diseases Intestinal Diseases Gastroenteritis Gastrointestinal Diseases Digestive System Diseases Vitamin D Ergocalciferols |
Vitamins Bone Density Conservation Agents Physiological Effects of Drugs Pharmacologic Actions Micronutrients Growth Substances |
ClinicalTrials.gov processed this record on May 19, 2013